CR1 Antibodies

CD35, also known as complement receptor 1 (CR1), is a membrane-bound glycoprotein encoded by the CR1 gene on chromosome 1q32.1. It consists of 2,039 amino acids, resulting in a molecular weight of approximately 190 kDa due to extensive glycosylation. Post-translational modifications of CD35 include phosphorylation and glycosylation. CD35 is a membrane protein that regulates the complement system, a key immune system component involved in host defense and inflammation. CD35 acts as a receptor for complement fragments C3b and C4b, facilitating their clearance from circulation and preventing excessive complement activation. Additionally, CD35 plays a role in immune complex clearance, antigen presentation, and modulation of T cell responses. 

CD35 is expressed on various immune cells, including erythrocytes, leukocytes, and certain tissue-resident macrophages. CD35 expression is regulated by various factors, including cytokines and inflammatory mediators, influencing its expression levels in different cell types and immune responses. Mutations in the CD35 gene or alterations in its expression have been associated with various autoimmune diseases, such as systemic lupus erythematosus (SLE) and autoimmune hemolytic anemia, where dysregulated complement activation contributes to disease pathology. While CD35 expression may not be directly used for disease diagnosis or prognosis, understanding its role in immune regulation and complement activation could have implications for immunotherapy strategies and treatment response.

NeoBiotechnologies offers a variety of antibodies against CD35 that have been validated for flow cytometry, immunofluorescence, and immunohistochemistry, as well as HuProt-validated options. Additionally, we hold exclusive rights to CD35 antibodies available for licensing or collaboration [https://www.neobiotechnologies.com/shop/page/2/?s=cd35].

Synonyms

Complement receptor type 1, C3BR|C4BR|CD35|KN

Research Areas

Apoptosis, Autophagy, Breast Cancer, Cancer, Cardiovascular, Cell Biology, Cellular Markers and Tags, Developmental Biology, Endocrine, Epigenetics, Gastrointestinal Tract, Hypoxia, Immuno Oncology, Immunology, Kidney, Lymphatic, Metabolism, Microbiology, Muscle, Neuroscience, Pancreatic Cancer, Prostate Cancer, Skin, Stem Cell, AKT Signaling, Angiogenesis, Articular Cartilage Extracellular Matrix, B Cell Markers, Basal Cell Marker, BBB VCAM-1 Signaling, Bladder Cancer, Cardiac Stem Cells, Colon Cancer, Colorectal Cancer, Complement System, CTLA-4 blockade immunotherapy, Cytokine Signaling, Defective Intrinsic Apoptosis, Dendritic Cell Marker, Digestion, Endothelial Cell Marker, Hematopoietic Stem Cells, Immune checkpoint, Infectious Disease, Lipid Metabolism, Lung Cancer, MAPK Signaling, Mast Cell Marker, Melanoma, Mesenchymal Stem Cell Differentiation, Mitochondria Marker, Neural Stem Cells, Neuroinflammation, Nuclear Marker, Oncology, Ovarian Cancer, PD-1 blockade immunotherapy, Signal Transduction, Stem Cell Differentiation, Transcription Factors

CR1

PARTNERSHIP OPPORTUNITIES

NeoBiotechnologies holds Exclusive rights to 10,000 recombinant and hybridoma antibody products, available for Licensing or Collaboration.

LETS TALK